In recent years, the research and development of oligonucleotide therapeutics has continued to gain momentum. Related industry collaborations, licensing and M&A remain active. To date, more than 20 oligonucleotide drugs have been approved globally. At the same time, the China domestic oligonucleotide drug sector is growing rapidly. Moreover, in addition to rare diseases, the development and application of oligonucleotide therapeutics have expanded heavily into chronic disease areas such as hyperlipidemia, cardiovascular diseases and infectious liver diseases etc. In the future, with the optimization of sequence design, structural modifications, improvement of delivery systems, clinical research and production scale, oligonucleotide therapeutics are expected to play an important role in the treatment of more diseases.

At the same time, with continuous research and investment in mRNA/circRNA technology domestically and internationally, the mRNA/circRNA field has made significant progress over the past year in the context of technology development, clinical application and market expansion. In addition to infectious disease vaccines, mRNA/circRNA technology has also been increasingly exploited to the development of personalized cancer vaccines, In vivo CAR-T/TCR-T therapies, protein replacement therapies for rare diseases, gene editing and regenerative medicine etc.

In Return, the xRNA Therapeutics Development and Innovation Forum will gather leaders and scientists across RNA-based medicines innovators, leading academic centers and institutes for the discussion to facilitate the communication and partnership for the efficient Development, Delivery and Manufacturing of the Next Generation mRNA/circRNA-based Vaccines/Therapeutics and Oligonucleotide Drugs.

xRNA Conference Major Sessions/Topics

• Recent Progress, Frontiers and Collaboration for Nucleic Acid Therapeutics Development
• mRNA/circRNA Vaccine and Therapeutics Development, Preclinical Research and Clinical Translation
• mRNA/circRNA Process Development and Production, Analytical Characterization and Quality Control
• mRNA/circRNA Cancer Vaccine and Cancer Immunotherapy
• mRNA/circRNA-based Advanced Therapies Development (In Vivo Cell Therapy, Gene Editing, Protein Replacement Therapy and Regenerative Medicine etc.)
• Oligonucleotide Drug Development, Preclinical Research and Clinical Translation
• Oligonucleotide Drug Process Development and Production,  Analytical Characterization and Quality Control
• Development and Application of Innovative Nucleic Acid Therapeutics Delivery Systems
• Investment and Collaboration in Nucleic Acid Therapeutics Industry
  
  

Currently we are receiving the podium/poster abstracts. If you are working in the above areas, you are invited to submit a proposal. For more information and latest availability, please contact:

Wei Zhang
Program Manager
Organizing Committee
Email: wzhang@deliver-consulting.com
Phone: 86-21-5269-8916